McGill Dept. of Equity, Ethics and Policy / Studies of Translation, Ethics, and Medicine (STREAM) is inviting applications for postdoctoral research fellow (PDF) for highly interdisciplinary research. Appropriate backgrounds include the social sciences, philosophy, decision sciences or epidemiology. Priority will be given to candidates with demonstrated knowledge of drug trials and a penchant for interdisciplinary work.
Applications should be sent electronically to: jonathan.kimmelman@mcgill.ca
STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
Kimmelman, J. (2025). A critique of the moral economy of pharmaceutical development. Critical Policy Studies, 1–19. https://doi-org.proxy3.library.mcgill.ca/10.1080/19460171.2025.2457529. Access PDF here: CritPol v1 WEB VERSIONc
Bicer, S., Nelson, A., Carayannis, K., & Kimmelman, J. (2024). Supporting Evidence in Phase 2 Cancer Trial Protocols: A Content Analysis. Journal of the National Cancer Institute, djae281. Advance online publication. https://doi.org/10.1093/jnci/djae281
Sheng, J., Zhang, A., Moyer, H., Hudson, M., Hazlewood, G., Strand, V., & Kimmelman, J. (2024). Explanation for substandard of care comparators in rheumatology randomised trial protocols. The Lancet. Rheumatology, 6(11), e743–e745. https://doi.org/10.1016/S2665-9913(24)00277-7
Kimmelman, J., Bodilly Kane, P., Bicer, S., & Carlisle, B. G. (2024). Preclinical assessment for translation to humans: The PATH approach for assessing supporting evidence for early-phase trials and innovative care. Med (New York, N.Y.), 5(10), 1227–1236. https://doiorg.proxy3.library.mcgill.ca/10.1016/j.medj.2024.07.014
Iskander, R., Moyer, H., Vigneault, K., Mahmud, S. M., & Kimmelman, J. (2024). Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis. JAMA, e246281. Advance online publication. https://doi.org/10.1001/jama.2024.6281
Iskander, R., Moyer, H., Fergusson, D., McGrath, S., Benedetti, A., & Kimmelman, J. (2024). The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis. Annals of internal medicine. 2024. doi:10.7326/M23-2515
Hutchinson N, Bicer S, Feldhake E, et al. Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies. JCO Oncol Pract. Published online December 18, 2023. doi:10.1200/OP.23.00363
Ouimet C, Hutchinson N, Wang C, Matyka C, Del Paggio JC, Kimmelman J. Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study. Sci Rep. 2023;13(1):16138. Published 2023 Sep 26. doi:10.1038/s41598-023-42213-y
Bicer S, Hutchinson N, Feldhake E, Nelson A, Oliviero E, Waligóra M, Kimmelman J. Timing for First-in-Minor Clinical Trials of New Cancer Drugs. J Pediatr. 2023 Aug 30:113705. doi: 10.1016/j.jpeds.2023.113705
London AJ, Kane PB, Kimmelman J. Varieties of community uncertainty and clinical equipoise. Kennedy Institute of Ethics Journal. 2023;33(1):1-9
Yu M, Montroy J, Fergusson D, Lalu MM, Kimmelman J. Matured Forecast Analyses for" Systematic and narrative review lead experts to different cancer trial predictions". Journal of clinical epidemiology. 2023 May 19:S0895-4356.
Jonathan Kimmelman quoted by The Boston Globe about expensive and unproven cancer drugs.
Jonathan Kimmelman quoted by Science News about the lack of reproducibility of pre-clinical cancer biology research.
Jonathan Kimmelman quoted by The Globe and Mail about the affordability and regulation of regenerative medicine.
Jonathan Kimmelman quoted by Science about poor quality science and how it contributes to misinformation in the media.
Jonathan Kimmelman quoted by STAT about social responsibility of medical practitioners.
Jonathan Kimmelman quoted by FiveThirtyEight about use of Ivermectin as a COVID-19 treatment.
Jonathan Kimmelman quoted by The Dallas Morning News about the testing of a new Covid-19 remedy backed by little evidence.
Jonathan Kimmelman quoted by Science about the use of Botox to ease depression.
Jonathan Kimmelman quoted by Fortune about the dangers of FDA emergency use authorizations.
Jonathan Kimmelman interviewed by The ASOS Press about important ethical considerations before launching a clinical cancer trials.
Jonathan Kimmelman quoted by Axios about the credibility of the AstraZeneca vaccine.
Jonathan Kimmelman quoted by The Harvard Crimson about reproducibility in science.
Jonathan Kimmelman quoted by CBC's Radio Canada about the impact of scientific papers published on pre-print servers.
Jonathan Kimmelman quoted in The National Post about Canada's decision to deviate from the dose schedules validated in clinical trials for COVID-19 vaccine administration.
Jonathan Kimmelman quoted in La Presse about the ethics of placebo-controlled clinical trials for approved COVID-19 vaccines.
Iskander, R., Moyer, H., Fergusson, D., McGrath, S., Benedetti, A., & Kimmelman, J. (2024). The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis. Annals of internal medicine. 2024. doi:10.7326/M23-2515
Hutchinson N, Bicer S, Feldhake E, et al. Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies. JCO Oncol Pract. Published online December 18, 2023. doi:10.1200/OP.23.00363
Ouimet C, Hutchinson N, Wang C, Matyka C, Del Paggio JC, Kimmelman J. Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study. Sci Rep. 2023;13(1):16138. Published 2023 Sep 26. doi:10.1038/s41598-023-42213-y
Bicer S, Hutchinson N, Feldhake E, Nelson A, Oliviero E, Waligóra M, Kimmelman J. Timing for First-in-Minor Clinical Trials of New Cancer Drugs. J Pediatr. 2023 Aug 30:113705. doi: 10.1016/j.jpeds.2023.113705
London AJ, Kane PB, Kimmelman J. Varieties of community uncertainty and clinical equipoise. Kennedy Institute of Ethics Journal. 2023;33(1):1-9
Yu M, Montroy J, Fergusson D, Lalu MM, Kimmelman J. Matured Forecast Analyses for" Systematic and narrative review lead experts to different cancer trial predictions". Journal of clinical epidemiology. 2023 May 19:S0895-4356.
Kimmelman J, Mandel DR, Benjamin DM. Predicting Clinical Trial Results: A Synthesis of Five Empirical Studies and Their Implications. Perspectives in Biology and Medicine. 2023;66(1):107-28.
Moyer H, Bittlinger M, Nelson A, Fernandez L, Sheng J, Wang Y, Del Paggio JC, Kimmelman J. Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials. Journal of Clinical Epidemiology. 2023 Apr 5.
Awan FA, Becker AB, Wang Y, Kimmelman J. Participant Recruitment From Low-and Middle-Income Countries for Pivotal Trials of Drugs Approved by the US Food and Drug Administration: A Cross-Sectional Analysis. Annals of Internal Medicine, Dec 2022
Jonathan Kimmelman quoted by The Boston Globe about expensive and unproven cancer drugs.
Jonathan Kimmelman quoted by Science News about the lack of reproducibility of pre-clinical cancer biology research.
Jonathan Kimmelman quoted by The Globe and Mail about the affordability and regulation of regenerative medicine.
Jonathan Kimmelman quoted by Science about poor quality science and how it contributes to misinformation in the media.
Jonathan Kimmelman quoted by STAT about social responsibility of medical practitioners.
Jonathan Kimmelman quoted by FiveThirtyEight about use of Ivermectin as a COVID-19 treatment.
Jonathan Kimmelman quoted by The Dallas Morning News about the testing of a new Covid-19 remedy backed by little evidence.
Jonathan Kimmelman quoted by Science about the use of Botox to ease depression.
Jonathan Kimmelman quoted by Fortune about the dangers of FDA emergency use authorizations.
Jonathan Kimmelman interviewed by The ASOS Press about important ethical considerations before launching a clinical cancer trials.
Jonathan Kimmelman quoted by Axios about the credibility of the AstraZeneca vaccine.
Jonathan Kimmelman quoted by The Harvard Crimson about reproducibility in science.
Jonathan Kimmelman quoted by CBC's Radio Canada about the impact of scientific papers published on pre-print servers.
Jonathan Kimmelman quoted in The National Post about Canada's decision to deviate from the dose schedules validated in clinical trials for COVID-19 vaccine administration.
Jonathan Kimmelman quoted in La Presse about the ethics of placebo-controlled clinical trials for approved COVID-19 vaccines.
All content © STREAM research
admin@translationalethics.com
Twitter: @stream_research
3647 rue Peel
Montreal QC H3A 1X1